Rheumatology Therapeutics Market Report 2026

The rheumatology therapeutics market size has grown steadily in recent years. It will grow from $44.18 billion in 2025 to $46.16 billion in 2026 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to increasing prevalence of rheumatoid arthritis and osteoarthritis, wider availability of nsaids and corticosteroids, improved diagnosis of rheumatic diseases, rising healthcare access in developed markets, growth in use of conventional synthetic dmards.

The rheumatology therapeutics market size is expected to see steady growth in the next few years. It will grow to $54.16 billion in 2030 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to rising demand for biologic dmards, increasing aging population with chronic joint disorders, growing awareness of early diagnosis and treatment, expansion of targeted synthetic dmards, increasing healthcare expenditure on chronic disease management. Major trends in the forecast period include growing adoption of biologic and targeted dmards, shift toward early and aggressive disease management, rising use of combination therapies in rheumatic diseases, increasing focus on long-term disease remission, expansion of personalized treatment approaches in rheumatology.

The increasing prevalence of autoimmune diseases is expected to drive the growth of the rheumatology therapeutics market in the coming years. An autoimmune disease is a condition in which the immune system mistakenly attacks and harms the body's own tissues. The prevalence of autoimmune diseases is rising due to a combination of genetic, environmental, and lifestyle factors, along with increased awareness and improved diagnostic capabilities. Rheumatology therapeutics are necessary for autoimmune diseases to manage inflammation, relieve symptoms, and prevent joint and tissue damage caused by the immune system targeting the body. For example, in June 2024, the Australian Institute of Health and Welfare, an Australia-based government agency, reported that approximately 514,000 people in Australia, or 2% of the population, were estimated to be living with rheumatoid arthritis in 2022. Rheumatoid arthritis accounted for 2% of the total disease burden and 16% of the burden for all musculoskeletal conditions in 2023. Consequently, the rising prevalence of autoimmune diseases is fueling the growth of the rheumatology therapeutics market.

Major companies in the rheumatology therapeutics market are focusing on developing innovative solutions, such as intravenous (IV) formulations, to improve treatment effectiveness and patient convenience. An intravenous (IV) formulation is a medication or substance administered directly into a vein via a needle or catheter. For example, in October 2023, Novartis AG, a Switzerland-based pharmaceutical company, announced that the US Food and Drug Administration (FDA) had approved Cosentyx in an intravenous (IV) formulation. This version of Cosentyx is specifically approved for treating adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA). It functions by selectively targeting and inhibiting interleukin-17A (IL-17A) and is the only non-tumor necrosis factor alpha (TNF-α) IV treatment available for these disorders.

In February 2024, Alfasigma S.p.A., an Italy-based pharmaceutical company, acquired the Jyseleca (filgotinib) business from Galapagos NV for $184.54 million. With this acquisition, Alfasigma has enhanced its product portfolio with an innovative pharmaceutical focused on gastrointestinal and rheumatological treatments. The acquisition also strengthens Alfasigma's presence in European markets by incorporating Jyseleca's business, which includes marketing authorizations throughout Europe and the UK, along with operations in commercialization, medical affairs, and development. Galapagos NV is a Belgium-based producer of rheumatology therapeutics.

Major companies operating in the rheumatology therapeutics market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Roche Holding AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., UCB S.A., Sanofi SA, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Janssen Biotech, Genentech Inc., Galapagos NV.

North America was the largest region in the rheumatology therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rheumatology therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rheumatology therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the rheumatology therapeutics market by increasing costs for imported active pharmaceutical ingredients, biologics manufacturing inputs, and cold-chain logistics essential for biologic dmards. These impacts are most evident in biologic and targeted synthetic drug segments and in regions dependent on cross-border pharmaceutical supply chains, particularly emerging markets. Higher tariffs may increase treatment costs and pressure reimbursement systems. However, tariffs have also encouraged local manufacturing of rheumatology drugs and biosimilars, strengthening domestic supply chains and improving long-term market resilience.

The rheumatology therapeutics market research report is one of a series of new reports that provides rheumatology therapeutics market statistics, including rheumatology therapeutics industry global market size, regional shares, competitors with a rheumatology therapeutics market share, detailed rheumatology therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the rheumatology therapeutics industry. This rheumatology therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Rheumatology therapeutics involve treatments designed to manage and relieve symptoms of rheumatic conditions, including arthritis, lupus, and gout. These treatments consist of medications such as anti-inflammatory drugs, disease-modifying antirheumatic drugs (DMARDs), and biologics, alongside physical therapy and lifestyle changes. The aim is to decrease inflammation, manage pain, and enhance the quality of life for patients.

The main rheumatology therapeutics include disease-modifying anti-rheumatic drugs, nonsteroidal anti-inflammatory drugs, corticosteroids, uric acid drugs, and others. Disease-modifying anti-rheumatic drugs (DMARDs) are a class of medications intended to slow or modify the underlying disease process in rheumatoid arthritis and other autoimmune disorders rather than merely relieve symptoms. These drugs are available through hospital pharmacies, retail pharmacies, and online pharmacies, and are used to treat rheumatoid arthritis, osteoarthritis, gout, psoriatic arthritis, ankylosing spondylitis, and other related conditions.

The rheumatology therapeutics market consists of revenues earned by entities by providing services such as diagnostic services, telemedicine, rehabilitation services, and lifestyle and nutritional counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The rheumatology therapeutics market also includes sales of biologic response modifiers, janus kinase (JAK) inhibitors, analgesics, and immunosuppressants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.